社区集群随机试验:减少阿片类药物过量死亡
该研究在肯塔基、马萨诸塞、纽约和俄亥俄4州的67个社区开展社区层面集群随机试验,干预组34个社区、等待名单对照组33个社区,按州分层。干预通过社区联盟推动过量教育及纳洛酮分发、阿片类使用障碍药物治疗和处方阿片安全三类循证实践。2021年7月至2022年6月比较期间,干预组与对照组阿片类过量死亡率相近(每10万人47.2例 vs 51.7例),校正率比0.91(95%CI 0.76–1.09;P=0.30)。干预社区从806项选定策略中实施了615项循证实践策略,但比较年开始时仅235项(38%)已启动。结论为在新冠大流行和芬太尼相关过量死亡流行背景下,两组死亡率相近。
要点
- 比较期2021年7月至2022年6月,干预组阿片类过量死亡每10万人47.2例 vs 对照组51.7例,校正率比0.91(95%CI 0.76–1.09;P=0.30)。
- 干预效果按州、城乡分类、年龄、性别、种族或族裔组均无明显差异。
- 干预社区从806项选定策略中实施615项循证实践策略:254项涉及过量教育及纳洛酮分发、256项涉及阿片类使用障碍药物治疗、105项涉及处方阿片安全。
- 上述循证实践策略中仅235项(38%)在比较年开始时已启动。
- 试验在新冠大流行与全国芬太尼相关过量死亡激增背景下进行,两组死亡率相近。
适用人群与场景
- 肯塔基、马萨诸塞、纽约和俄亥俄4州的67个社区(干预组34个、等待名单对照组33个),按州分层,组内按城乡分类、既往过量率、社区人口平衡。
- 主要结局为社区成人中阿片类药物过量死亡数。
处置流程与药物剂量
- 干预通过社区联盟推动三类循证实践:过量教育及纳洛酮分发、阿片类使用障碍药物治疗、处方阿片安全。
- 干预社区从806项选定策略中实施615项循证实践策略(254项过量教育及纳洛酮分发、256项阿片类使用障碍药物治疗、105项处方阿片安全)。
- 比较年开始时仅235项(38%)循证实践策略已启动。
研究设计与关键结果
- 社区层面集群随机试验,67个社区(干预组34个、等待名单对照组33个),比较期为2021年7月至2022年6月。
- 主要结局:干预组阿片类过量死亡每10万人47.2例 vs 对照组每10万人51.7例,校正率比0.91(95%CI 0.76–1.09;P=0.30)。
- 干预效果按州、城乡分类、年龄、性别、种族或族裔组均无明显差异。
- 干预社区从806项选定策略中实施615项循证实践策略,其中仅235项(38%)在比较年开始时已启动。
证据类型、等级与局限
- 证据类型:社区层面集群随机试验(HCS,ClinicalTrials.gov NCT04111939),由美国国立卫生研究院资助。
- 局限:试验在新冠大流行与全国芬太尼相关过量死亡激增背景下进行;比较年开始时仅38%的循证实践策略已启动。
对床旁实践的改变
- 该试验显示,在新冠大流行与芬太尼相关过量死亡激增背景下,社区联盟推动循证实践的多模式干预12个月未显著降低阿片类过量死亡率(校正率比0.91,95%CI 0.76–1.09;P=0.30)。
- 干预效果按州、城乡分类、年龄、性别、种族或族裔组均无明显差异。
- 干预社区实施615项循证实践策略,但比较年开始时仅235项(38%)已启动。
指南或共识出处
- HCS ClinicalTrials.gov number, NCT04111939
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence-based practices for reducing opioid-related overdose deaths include overdose education and naloxone distribution, the use of medications for the treatment of opioid use disorder, and prescription opioid safety. Data are needed on the effectiveness of a community-engaged intervention to reduce opioid-related overdose deaths through enhanced uptake of these practices.
METHODS: In this community-level, cluster-randomized trial, we randomly assigned 67 communities in Kentucky, Massachusetts, New York, and Ohio to receive the intervention (34 communities) or a wait-list control (33 communities), stratified according to state. The trial was conducted within the context of both the coronavirus disease 2019 (Covid-19) pandemic and a national surge in the number of fentanyl-related overdose deaths. The trial groups were balanced within states according to urban or rural classification, previous overdose rate, and community population. The primary outcome was the number of opioid-related overdose deaths among community adults.
RESULTS: During the comparison period from July 2021 through June 2022, the population-averaged rates of opioid-related overdose deaths were similar in the intervention group and the control group (47.2 deaths per 100,000 population vs. 51.7 per 100,000 population), for an adjusted rate ratio of 0.91 (95% confidence interval, 0.76 to 1.09; P = 0.30). The effect of the intervention on the rate of opioid-related overdose deaths did not differ appreciably according to state, urban or rural category, age, sex, or race or ethnic group. Intervention communities implemented 615 evidence-based practice strategies from the 806 strategies selected by communities (254 involving overdose education and naloxone distribution, 256 involving the use of medications for opioid use disorder, and 105 involving prescription opioid safety). Of these evidence-based practice strategies, only 235 (38%) had been initiated by the start of the comparison year.
CONCLUSIONS: In this 12-month multimodal intervention trial involving community coalitions in the deployment of evidence-based practices to reduce opioid overdose deaths, death rates were similar in the intervention group and the control group in the context of the Covid-19 pandemic and the fentanyl-related overdose epidemic. (Funded by the National Institutes of Health; HCS ClinicalTrials.gov number, NCT04111939.).
参考来源
- Samet JH, El-Bassel N, Winhusen TJ, et al. Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths. N Engl J Med. 2024. PMID: 38884347. doi:10.1056/NEJMoa2401177
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。